皮里多斯提格治疗儿科轴突基兰-巴雷综合征的治疗方法
E Zohar-Dayan1,2, J Landa2,3, S Barak3,4
1Pediatric Neurologic Unit, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medica Center, Tel Hashomer, Ramat-Gan, Israel.
Muscle & nerve
|February 6, 2026
概括
作为一种乙胆酶抑制剂的皮里多斯提格,作为对儿科轴突基因巴雷综合征 (GBS) 的补充疗法,显示出前景. 这种治疗改善了那些对标准免疫疗法没有反应的患者的运动功能和运动能力,即使在疾病过程中晚些时候开始治疗.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经肌肉结 (NMJ) 参与了吉兰-巴雷综合征 (GBS) 病变的发生.
- 在GBS中,直接针对NMJ进行治疗仍然不常见.
- 轴状GBS带来了重大的运动和功能挑战.
研究的目的:
- 评估pyridostigmine作为儿科轴突GBS的辅助治疗的疗效和安全性.
- 评估皮里多斯提格对运动力,行走能力和功能技能的影响.
- 为了确定pyridostigmine是否可以在GBS晚期阶段或在免疫治疗反应不佳的情况下有益.
主要方法:
- 四名患有轴突性GBS的儿科患者接受了标准免疫疗法.
- 皮里多斯蒂格作为一种附加治疗,在疾病发病和平原后几周到几个月后开始使用.
- 使用6分钟步行测试,手动肌肉测试 (四肢体,腿筋),儿童残疾库存-功能技能评估 (PEDI-FS) 和GBS残疾评分来评估有效性,比较治疗前和治疗期间的值.
主要成果:
- 所有患者在皮里多斯提格治疗一个月后,运动和功能能力显著改善.
- 肌肉力量 (四肢体,腿筋) 在手动肌肉测试中至少增加两分.
- 步行距离提高了10-272米,PEDI-FS移动性得分增加了22.3-34.7分.
- 在皮里多斯提格治疗期间没有报告任何严重不良事件.
结论:
- 皮里多斯提格可以作为儿童轴突GBS患者的安全有效的补充疗法.
- 这种治疗对于那些对标准免疫疗法反应不足的人来说似乎是有益的.
- 即使在疾病晚期启动,也可能是一个可行的选择,需要在更大的研究中进一步调查.
相关概念视频
01:21Neurons: The Axon
7.4K
Axons are long, cytoplasmic processes of nerve cells capable of propagating electrical impulses known as action potentials. The cytoplasm or axoplasm of an axon contains neurofibrils, neurotubules, small vesicles, lysosomes, mitochondria, and various enzymes, all encased within the axolemma, the plasma membrane of the axon.
The axon attaches to the cell body at a cone-shaped elevation called the axon hillock. The initial part of the axon, closest to the hillock, is known as the initial segment....
The axon attaches to the cell body at a cone-shaped elevation called the axon hillock. The initial part of the axon, closest to the hillock, is known as the initial segment....
7.4K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
266
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
01:24Nephrotic Syndrome I : Introduction
661
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
661
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
314
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
237
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
237
01:30Acute Coronary Syndrome I: Introduction
1.0K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.0K